Investigating the effects of human disturbance on species abundance in near pond and impermeable habitats by Balsharn Heir (3113820)

“…Quadrats (0.5 x 0.5m) were randomly placed every two meters, alternating left and right, along a 50m transect. …”

Developmental analysis of Brn3b+ neurons in the dorsal midbrain using the <i>Brn3b</i>^GFP/+ mouse. by Hyoseo Lee (17419987)

“…Unpaired two-tailed Student’s <i>t</i> test (mean ± SEM; <i>p</i> = 0.029 [*] for the cell number and <i>p</i> = 0.013 [*] for the distribution). …”

Interaction between Coastal and Oceanic Ecosystems of the Western and Central Pacific Ocean through Predator-Prey Relationship Studies by Valerie Allain (164517)

“…We show that reef organisms are a frequent prey of oceanic predators. …”

Data_Sheet_1_Functional comorbidities and brain tissue changes before and after lung transplant in adults.PDF by Matthew Scott Vandiver (14206463)

“…T1-weighted images were partitioned into gray matter (GM)-tissue type, normalized to a common space, smoothed, and the smoothed GM-volume maps were compared between pre- and post-transplant (paired t-tests; covariate, age; SPM12, p < 0.005).…”

Image_1_Letrozole cotreatment improves the follicular output rate in high-body-mass-index women with polycystic ovary syndrome undergoing IVF treatment.jpeg by Yali Liu (12074)

“…The implantation rate in the study group was numerically higher but without statistic significant than that in the control groups (43.15% (107/248) vs. 38.59% (115/298), OR 1.008, 95% CI 0.901-1.127; P >.05).</p>Conclusion<p>The effect of LE combined with PPOS on FORT is better than the effect of the standard PPOS treatment in women with PCOS and a high BMI, but there is no substantially beneficial impact on pregnancy outcomes or the cycle features of COS, including consumption of hMG.…”

Table_1_Letrozole cotreatment improves the follicular output rate in high-body-mass-index women with polycystic ovary syndrome undergoing IVF treatment.docx by Yali Liu (12074)

“…The implantation rate in the study group was numerically higher but without statistic significant than that in the control groups (43.15% (107/248) vs. 38.59% (115/298), OR 1.008, 95% CI 0.901-1.127; P >.05).</p>Conclusion<p>The effect of LE combined with PPOS on FORT is better than the effect of the standard PPOS treatment in women with PCOS and a high BMI, but there is no substantially beneficial impact on pregnancy outcomes or the cycle features of COS, including consumption of hMG.…”

Change in LDL cholesterol and PCSK9 from baseline according to treatment groups. by Heiner K. Berthold (344265)

“…<p>Data are means ± SEM. The decrease in LDL cholesterol was significant in all groups (all <i>P</i><0.0001), the increase in PCSK9 was significant in the simvastatin and in the combination groups (<i>P</i><0.005), but not in the ezetimibe group.…”

Presentation 1_Granola consumption with multiple prebiotics in Japanese participants increases Bifidobacterium abundance and improves stress and subjective sleepiness.pptx by Hiroyuki Sasaki (28675)

“…Correlation analysis suggested a significant association between increased Bifidobacterium level and reduced stress (r = −0.39, p = 0.0035) and insomnia levels (r = −0.3, p = 0.026).…”

Image 5_MIF tautomerase inhibitor TE-11 prevents inflammatory macrophage activation and glycolytic reprogramming while reducing leukocyte migration and improving Crohn’s disease-li... by Eszter Vámos (11081587)

“…Leukocyte recruitment, M1 macrophage polarization and associated metabolic reprogramming are hallmarks of its pathomechanism. Here, we tested TE-11, a potent MIF tautomerase inhibitor (IC₅₀ = 5.63 μmol/dm³) in experimental Crohn’s disease in male mice, in leukocyte recruitment and in inflammatory M1 macrophage activation.…”

Image 2_MIF tautomerase inhibitor TE-11 prevents inflammatory macrophage activation and glycolytic reprogramming while reducing leukocyte migration and improving Crohn’s disease-li... by Eszter Vámos (11081587)

“…Leukocyte recruitment, M1 macrophage polarization and associated metabolic reprogramming are hallmarks of its pathomechanism. Here, we tested TE-11, a potent MIF tautomerase inhibitor (IC₅₀ = 5.63 μmol/dm³) in experimental Crohn’s disease in male mice, in leukocyte recruitment and in inflammatory M1 macrophage activation.…”

Image 1_MIF tautomerase inhibitor TE-11 prevents inflammatory macrophage activation and glycolytic reprogramming while reducing leukocyte migration and improving Crohn’s disease-li... by Eszter Vámos (11081587)

“…Leukocyte recruitment, M1 macrophage polarization and associated metabolic reprogramming are hallmarks of its pathomechanism. Here, we tested TE-11, a potent MIF tautomerase inhibitor (IC₅₀ = 5.63 μmol/dm³) in experimental Crohn’s disease in male mice, in leukocyte recruitment and in inflammatory M1 macrophage activation.…”

Image 4_MIF tautomerase inhibitor TE-11 prevents inflammatory macrophage activation and glycolytic reprogramming while reducing leukocyte migration and improving Crohn’s disease-li... by Eszter Vámos (11081587)

“…Leukocyte recruitment, M1 macrophage polarization and associated metabolic reprogramming are hallmarks of its pathomechanism. Here, we tested TE-11, a potent MIF tautomerase inhibitor (IC₅₀ = 5.63 μmol/dm³) in experimental Crohn’s disease in male mice, in leukocyte recruitment and in inflammatory M1 macrophage activation.…”

Image 3_MIF tautomerase inhibitor TE-11 prevents inflammatory macrophage activation and glycolytic reprogramming while reducing leukocyte migration and improving Crohn’s disease-li... by Eszter Vámos (11081587)

“…Leukocyte recruitment, M1 macrophage polarization and associated metabolic reprogramming are hallmarks of its pathomechanism. Here, we tested TE-11, a potent MIF tautomerase inhibitor (IC₅₀ = 5.63 μmol/dm³) in experimental Crohn’s disease in male mice, in leukocyte recruitment and in inflammatory M1 macrophage activation.…”

Elimination of <i>tp53</i> function partially rescues <i>tert^−/−</i> degeneration in proliferative tissues. by Catarina M. Henriques (102294)

“…Data are represented as mean +/− SEM. Scale bar = 50 µm.</p>…”

Supplementary Material for: Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease by Martin E.R. (3859435)

“…Compared with placebo, vadadustat significantly increased Hb after 6 weeks in a dose-dependent manner (analysis of variance; <i>p </i>< 0.0001). …”

PowerPoint Slides for: Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease by Martin E.R. (3859435)

“…Compared with placebo, vadadustat significantly increased Hb after 6 weeks in a dose-dependent manner (analysis of variance; <i>p </i>< 0.0001). …”

Data_Sheet_1.pdf by Xinyu Wang (341591)

“…The initial PNP increased from 50 to 130 mg L^-1 and the k_PNP decreased from 0.093 ± 0.008 to 0.027 ± 0.001 h^-1. …”

Altered virulence of Highly Pathogenic Avian Influenza (HPAI) H5N8 reassortant viruses in mammalian models by Su-Jin Park (124392)

“…Of note, substitution of the PB2 gene segment of the H5N8 virus by that from the H5N1 virus resulted in a 1000-fold increase in virulence for mice compared with the parental virus (MLD₅₀ decreased from 10^5.8 to 10^2.5 EID₅₀). …”

Image1_Comprehensive in vitro and in silico assessments of metabolic capabilities of 24 genomic variants of CYP2C19 using two different substrates.TIF by Myung-Eui Seo (6822518)

“…The five variants with decreased metabolic capability (<50%) of wild type for either substrates were evaluated as protein damaging by all three in silico prediction algorithms, except CADD exact score of NM_000769.4:c.593T>C that was 19.68 (<20.0). …”

Image 4_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…Our updated analysis confirmed at PC therapy significantly improves OS (hazard ratio [HR]: 0.73 [0.69, 0.77], P < 0.00001), PFS (HR: 0.56 [0.52, 0.60], P < 0.00001), duration of response (DOR, HR: 0.50 [0.45, 0.54], P < 0.00001) and objective response rate (ORR, risk ratio [RR]: 1.59 [1.51, 1.67], P < 0.00001) compared to chemotherapy alone. …”